Metabolon Introduces mSelect(TM) To Improve Selection Of Drug Candidates

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Sept. 18, 2006--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery used for disease diagnosis and drug safety and efficacy testing, announced today the launch of mSelect(TM), a service offering that empowers researchers in early drug discovery to select the most promising and lowest-risk drug candidates for continued development.

Back to news